口服肝脏限制性LXR反向激动剂治疗血脂异常:临床前开发与1期试验
研究开发了肠道和肝脏限制性口服LXR反向激动剂TLC-2716,在人类肝脏类器官中减少脂质蓄积并抑制炎症和纤维化基因表达;随机安慰剂对照1期试验中14天治疗耐受良好,血浆甘油三酯和餐后残粒胆固醇分别较安慰剂降低最高38.5%和61%。
要点
- TLC-2716为口服肠道和肝脏限制性LXR反向激动剂。
- 1期试验14天治疗耐受良好(主要终点)。
- 血浆TG和餐后残粒胆固醇较安慰剂降低最高38.5%和61%。
核心结论
- TLC-2716耐受良好并具有治疗血脂异常、降低动脉粥样硬化性心血管疾病残余风险的潜力。
研究设计与样本
- 临床前研究包括人类肝脏类器官模拟脂肪性肝炎模型。
- 随机、安慰剂对照1期临床试验(NCT05483998),14天治疗,主要终点为耐受性。
主要发现
- 在人类肝脏类器官脂肪性肝炎模型中,TLC-2716减少脂质蓄积并抑制炎症和纤维化基因表达。
- 1期试验中14天治疗耐受良好(主要终点)。
- 血浆甘油三酯较安慰剂降低最高38.5%(次要终点)。
- 餐后残粒胆固醇较安慰剂降低最高61%(次要终点)。
关键数值与推荐
- 血浆甘油三酯安慰剂校正降低最高38.5%。
- 餐后残粒胆固醇安慰剂校正降低最高61%。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite advances in lipid-lowering treatment, atherosclerotic cardiovascular disease remains the leading cause of mortality, underscoring the need to address residual risk. Targeting both the synthesis and clearance of triglyceride (TG)-rich lipoproteins is a promising approach. Liver X receptor (LXR) repression can reduce plasma TG and cholesterol and improve insulin sensitivity by suppressing de novo lipogenesis and intestinal lipid absorption and enhancing clearance of TG-rich lipoproteins, but its clinical utility remains unexplored. Here we demonstrate the role of LXR inverse agonists in lipid metabolism and metabolic diseases in preclinical models and humans. Given concerns that systemic LXR repression may impair reverse cholesterol transport, we developed TLC-2716, an orally administered, gut- and liver-restricted LXR inverse agonist. In human liver organoids modeling steatohepatitis, TLC-2716 reduced lipid accumulation and suppressed inflammation and fibrotic gene expression. In a randomized, placebo-controlled phase 1 clinical trial, 14-day treatment with TLC-2716 was well tolerated (primary endpoints) and resulted in placebo-adjusted reductions up to 38.5% in plasma TG and 61% in postprandial remnant cholesterol (secondary endpoints). In conclusion, these results highlight the tolerability and therapeutic potential of TLC-2716 as a treatment for managing dyslipidemia and reducing residual atherosclerotic cardiovascular disease risk in humans. ClinicalTrials.gov identifier: NCT05483998 .
引用
- Li X, Benegiamo G, Vijayakumar A, et al. An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial. Nat Med. 2026. PMID: 41545590. doi:10.1038/s41591-025-04169-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。